FDA Investigator Kejun Cheng
Kejun Cheng has conducted inspections on 8 sites in 4 countries as of 19 Jun 2024. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
8
Last Inspection Date:
19 Jun 2024
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
India,
United Kingdom of Great Britain and Northern Ireland,
Italy,
Spain
FDA Investigators that have inspected at least one site in common with Kejun Cheng:
Angela E Glenn,
Azza Talaat,
Barbara Janine Breithaupt,
Brandon C Heitmeier,
Brittany D Terhar,
Carla A Norris,
CDR Ileana Barreto Pettit,
Charanjeet Jassal,
Charisse K Green,
Cynthia Jim, CSO,
Daniel J Roberts,
Daniel L Obrzut,
Darren S Brown,
Deborah A Greco,
Dongping Dai, PhD,
Dr. Barbara D Paul, PhD,
Emilie E Kahn,
Eric M Mueller, PharmD,
Farhana Khan,
Gayle S Lawson,
Jazmine N Brown,
Jeffery A Hangartner,
Jeffrey P Raimondi,
Jennifer L Huntington,
Jorge L Guadalupe,
José E Meléndez,
Jose M Cayuela,
Jose Martinez, Jr,
Jose Velez,
Junho Pak,
Justin A Boyd,
Katherine Szestypalow,
Kellia N Hicks,
Kenneth H Williams,
Kham Phommachanh,
Kristy A Zielny,
Lindsey S Fleischman,
Lucas B Leake,
Marcellinus D Dordunoo,
Maria A Reed,
Monica Cburgos Garcia,
Muralidhara B Gavini, PhD,
Neal L Adams,
Neil J Bonzagni, PhD MPH,
Nicole E Knowlton,
Paraluman S Leonin,
Parul M Patel,
Patrick C Klotzbuecher,
Pratik S Upadhyay, DDC,
Rebecca E Dombrowski,
Rose Xu,
Rumany C Penn, PharmD,
Saied A Asbagh,
Saleem A Akhtar,
Santos E Camara,
Sarah Ibrahim,
Sarah M Meng,
Satheesh Thomas,
Scott B Laufenberg,
Scott T Ballard,
Shirley J Berryman,
Simone E Pitts,
Sixto M Mercado Rios,
Sony Mathews,
Stephen D Brown,
Steven P Donald,
Susan M Jackson,
Susan T Hadman,
Taichun Qin, PhD,
Tamil Arasu, PhD,
Thomas J Arista,
Vilmary Negron Rodriguez,
Walden H Lee,
William J Leonard,
Yumi J Hiramine,
Yvins Dezan
Kejun Cheng's Documents
Publish Date | Document Type | Title |
---|---|---|
June, 2019 | EIR | Sun Pharmaceutical Industries Limited - EIR, 2019-06-11 |
June, 2019 | FDA 483 | Sun Pharmaceutical Industries Limited - Form 483, 2019-06-11 |
May, 2019 | FDA 483 | Intas Pharmaceuticals Limited - Form 483, 2019-05-28 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more